PiSA Targeting Contract Manufacturing Opportunities


PiSA Farmaceutica, which claims to be Mexico’s largest pharmaceutical company, is expanding its presence in contract manufacturing. The company has seven facilities manufacturing pharmaceuticals, including injectables and oral dose forms, as well plants manufacturing medical devices and wound dressings. Pharmaceutical capabilities include hormone, cephalosporin, cytotoxic and biopharmaceutical products.

“We export contract-manufactured devices; we started in 2007 and have had two-digit growth year-over-year,” Jeff Hover, president of PiSA Biopharm, told PharmSource. “Sterile fluid contract manufacturing has quadrupled over the last few years.”

PiSA has three facilities that offer injection molding of packaging through fill/finish operations, he noted, and recently received approval to make large volume parenterals for sale in Canada. Over the next five years, PiSA expects to increase exports up to 5% and is planning a new plant that will be 80% dedicated to exports.

Contract manufacturing has become an opportunity for Mexican companies with excess capacity, noted Geraldine du Tilly, a consultant with Russell Reynolds Associates, in a white paper published on the firm’s website, as well as for dedicated CMOs. According to PharmSource’s analysis, 17 Mexican companies currently offer contract manufacturing services in the country (see table below). Much of the Mexican pharma industry traditionally has focused on…

This article is reprinted from the December 2014 issue of Emerging Markets Outsourcing Report. To learn more, click here.

Read more postings by Lisa

Lisa serves as the Managing Editor at PharmSource. She holds a BS degree in journalism from Radford University, and has over 20 years of experience in editing, writing and managing newsletters and other print media, including B2B publications related to industries including science, pharmaceuticals, biologics and medical devices.

More posts by Lisa Tilley Hinkle